A PYMNTS Company

Endo Wins Against Opana Purchasers’ Antitrust Claims

By  |  July 3, 2022

A jury on Friday sided with drugmaker Endo International Plc against purchasers of its opioid painkiller Opana ER who had accused it of delaying the launch of a generic version of the drug through an illegal deal with a competitor.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The jury in Chicago federal court rejected claims by a class of purchasers that bought from Opana directly, led by drug wholesalers; a class of indirect purchasers, led by several employee health plans and Blue Cross and Blue Shield of Louisiana; and several individual retailers including Walgreens Boots Alliance and Kroger Co.

    “Endo is very pleased with the jury’s verdict and is grateful for its careful deliberation,” Endo Chief Legal Officer Matthew Maletta said in a statement.

    The litigation, which began in 2014, centers on a 2008 settlement between Endo and generic drugmaker Impax Laboratories, which is now owned by Amneal Pharmaceuticals.

    Impax was originally a defendant as well but settled during trial.

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.